IMPEL NEUROPHARMA INC's ticker is IMPL and the CUSIP is 45258K109. A total of 33 filers reported holding IMPEL NEUROPHARMA INC in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $217,249 | -66.3% | 505,231 | -0.5% | 0.00% | – |
| Q2 2023 | $645,002 | -10.4% | 507,876 | -1.2% | 0.00% | – |
| Q1 2023 | $719,698 | -62.7% | 514,070 | 0.0% | 0.00% | – |
| Q4 2022 | $1,927,763 | -23.0% | 514,070 | +0.0% | 0.00% | – |
| Q3 2022 | $2,503,000 | -47.7% | 513,868 | 0.0% | 0.00% | – |
| Q2 2022 | $4,790,000 | +41.4% | 513,868 | -3.4% | 0.00% | – |
| Q1 2022 | $3,387,000 | -20.2% | 531,784 | +8.1% | 0.00% | – |
| Q4 2021 | $4,244,000 | -4.4% | 491,752 | +34.9% | 0.00% | – |
| Q3 2021 | $4,440,000 | +172.9% | 364,541 | +98.4% | 0.00% | – |
| Q2 2021 | $1,627,000 | – | 183,753 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| LASRY MARC | 408,329 | $1,989,000 | 3.82% |
| venBio Partners LLC | 2,759,791 | $13,440,000 | 3.11% |
| 5AM Venture Management, LLC | 2,884,791 | $14,049,000 | 2.69% |
| Vivo Capital, LLC | 2,884,789 | $14,049,000 | 1.55% |
| DCF Advisers, LLC | 469,183 | $2,285,000 | 1.48% |
| Opaleye Management Inc. | 255,250 | $1,243,000 | 0.51% |
| Kohlberg Kravis Roberts & Co. L.P. | 4,135,971 | $20,142,000 | 0.40% |
| EPIQ PARTNERS, LLC | 18,646 | $91,000 | 0.06% |
| GILDER GAGNON HOWE & CO LLC | 142,696 | $695,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 68,300 | $333,000 | 0.01% |